Impact of Immunotherapy After Surgery for Lung Cancer
Author Information
Author(s): Dong Yichen MD, Xu Long MD, Wen Jialiang MD, Si Haojie MD, Yu Juemin MD, Chen Tao MD, Xie Huikang MD, Li Xinjian MD, Yang Minglei MD, Fan Junqiang MD, Wu Junqi MD, She Yunlang MD, Zhao Deping MD, Chen Chang MD, PhD
Primary Institution: Shanghai Pulmonary Hospital, Tongji University School of Medicine
Hypothesis
Does adjuvant immunotherapy improve survival in patients with resectable NSCLC after neoadjuvant chemoimmunotherapy?
Conclusion
Adjuvant immunotherapy significantly improves recurrence-free and overall survival in patients with resectable NSCLC after neoadjuvant treatment, with six cycles being the optimal regimen.
Supporting Evidence
- 29.7% of patients achieved a pathologic complete response.
- Patients receiving adjuvant immunotherapy had significantly better recurrence-free survival.
- Six cycles of adjuvant immunotherapy were identified as the optimal regimen.
Takeaway
Giving extra treatment after surgery can help lung cancer patients live longer, especially if they get six rounds of it.
Methodology
This retrospective study analyzed 438 patients who received neoadjuvant chemoimmunotherapy and evaluated their outcomes based on adjuvant immunotherapy.
Potential Biases
Potential selection bias due to the retrospective design.
Limitations
The study's retrospective nature may introduce selection bias, and the sample size for adjuvant immunotherapy was limited.
Participant Demographics
Patients diagnosed with clinical stage IB to IIIB NSCLC, with a mix of ages and genders.
Statistical Information
P-Value
0.037
Confidence Interval
0.41–0.98
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website